Neutropenia
Recent clinical, regulatory, research and industry developments relating to this disease.
CHMP positive opinion: Neuzafy (EMA)
Biosimilar medicine authorisation: Cavoley (EMA)
A Phase I Study of MozobilTM in the Treatment of Patients With WHIMS
CHMP positive opinion: Cavoley (EMA)
Biosimilar medicine authorisation: Vivlipeg (EMA)
Biosimilar medicine authorisation: Dyrupeg (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2027.
- 2 industry developments reported.
- Q3 2027A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- Q3 2027Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.
- Q1 2028Prospective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
Clinical MilestonesViewHide
- 2026-09-18Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.Results expected Q3 2027
- 2026-08-06A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsResults expected Q3 2027
- 2026-04-16Prospective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged NeutropeniaResults expected Q1 2028
- 2026-10-31A Multicenter, Exploratory Clinical Study of Efbemalenograstim Alfa-vuxw Injection for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FNPrimary completion
- 2026-06-30A Phase III Clinical Study of the Efficacy and Safety of Polyethylene Glycolized Human Granulocyte Stimulating Factor Injection (PEG-G-CSF) in Preventing Neutropenia After ChemotherapyPrimary completion
- 2025-12-30A Randomized, Open-label, Interventional, Real-world Study to Compare the Efficacy and Safety of QL0605 Administered at Different Timepoints After Chemotherapy.Primary completion
- 2025-12-17Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile NeutropeniaCompleted
Industry & MarketViewHide
- 2026-10-08CSF Delivery Method Not Tied to Febrile Neutropenia RiskIndustry · Medscape Medical News
- 2026-09-03Serious Neutropenia in Clozapine Use: Rare, Occurs EarlyIndustry · Medscape Medical News
Regulatory UpdatesViewHide
- 2026-10-16CHMP positive opinion — FilgrastimTreatment of neutropenia in adults and children
- 2026-07-24CHMP positive opinion — PegfilgrastimReduction of neutropenia in adults
- 2026-10-31ClinicalA Multicenter, Exploratory Clinical Study of Efbemalenograstim Alfa-vuxw Injection for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FNPrimary completion
- 2026-10-16RegulatoryCHMP positive opinion — FilgrastimTreatment of neutropenia in adults and children
- 2026-10-08IndustryCSF Delivery Method Not Tied to Febrile Neutropenia RiskIndustry · Medscape Medical News
- 2026-09-18ClinicalCeftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.Results expected Q3 2027
- 2026-09-03IndustrySerious Neutropenia in Clozapine Use: Rare, Occurs EarlyIndustry · Medscape Medical News
- 2026-08-06ClinicalA Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsResults expected Q3 2027
- 2026-07-24RegulatoryCHMP positive opinion — PegfilgrastimReduction of neutropenia in adults
- 2026-06-30ClinicalA Phase III Clinical Study of the Efficacy and Safety of Polyethylene Glycolized Human Granulocyte Stimulating Factor Injection (PEG-G-CSF) in Preventing Neutropenia After ChemotherapyPrimary completion
- 2026-04-16ClinicalProspective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged NeutropeniaResults expected Q1 2028
- 2025-12-30ClinicalA Randomized, Open-label, Interventional, Real-world Study to Compare the Efficacy and Safety of QL0605 Administered at Different Timepoints After Chemotherapy.Primary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Biosimilar approval — Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adul… (2026)
Original application approval — Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence… (2024)
Generic approval — Posaconazole Accord is indicated for use in the treatment of the following fungal infecti… (2019)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Neutropenia2
- Antibodies, Monoclonal1
- Breast Neoplasms1
- Carcinoma, Transitional Cell1
- Erb-b2 Receptor Tyrosine Kinases1
- Immunoconjugates1
- Immunotherapy, Adoptive1
- Oligopeptides1
Leading journals5
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology4
- The New England journal of medicine4
- Blood1
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
- The oncologist1
Leading researchers8
- Locke FL2
- Ackermann J1
- Ackland SP1
- Alesini D1
- Amellal N1
- Antón A1
- Armstrong D1
- Avivi I1
Affiliations (unnormalised)6
- "S. Carlo" Hospital1
- "Sapienza" University of Rome1
- and German Cancer Research Center1
- Anhui Provincial Cancer Hospital1
- Antwerp University Hospital1
- AOU Policlinico Umberto I1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Neutropenia is a reduction in the number of neutrophils in the blood. It is a hematologic abnormality rather than a single disease entity, and it is often discussed in the context of treatment-related blood count suppression.
The supplied grounding supports drug-associated neutropenia in the setting of drug therapy. It is co-studied with agents such as docetaxel, fluorouracil, and camptothecin, indicating that chemotherapy exposure is a recognized cause in the literature provided.
The core biological feature is depletion of circulating neutrophils. In the supplied literature context, this is discussed as a consequence of drug therapy, consistent with suppression of neutrophil production or survival during treatment.
Exposure to drug therapy, particularly chemotherapy agents such as docetaxel, fluorouracil, and camptothecin, is supported as a risk factor in the supplied grounding. The provided material does not support additional risk factors.
The supplied grounding only indicates that the literature covers drug therapy, without specifying a particular treatment approach for neutropenia itself. No standard treatment modality or drug class can be stated from the provided material.
AI-generated summary grounded in MeSH. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A decrease in the number of NEUTROPHILS found in the blood.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.